

Submission Data File

General Information	
Form Type*	6-K
Contact Name	M2 Compliance
Contact Phone	754-243-5120
Filer File Number	
Filer CIK*	0001849296 (OKYO Pharma Ltd)
Filer CCC*	*****
Confirming Copy	No
Notify via Website only	No
Return Copy	Yes
SROS*	NONE
Period*	
(End General Information)	

Document Information	
File Count*	2
Document Name 1*	form6-k.htm
Document Type 1*	6-K
Document Description 1	
Document Name 2*	ex99-1.htm
Document Type 2*	EX-99.1
Document Description 2	
(End Document Information)	

Notifications	
Notify via Website only	No
E-mail 1	filing@m2compliance.com
(End Notifications)	

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

September 2022

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9th Floor
107 Cheapside
London
EC2V 6DN

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 7, 2022, OKYO Pharma LTD (the "Company") issued a news service announcement in the United Kingdom announcing the Result of the Annual General Meeting.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OKYO Pharma LTD

Date: September 7, 2022

By: /s/ Gary Jacob

Name: Gary Jacob

Title: Chief Executive Officer

EXHIBIT INDEX

**Exhibit
No.**

Description

99.1 [News Service Announcement, dated September 7, 2022](#)

Exhibit 99.1

7 September 2022

OKYO Pharma Limited

("OKYO" or "Company")

Result of Annual General Meeting

The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeting ("AGM") of the Company held earlier today all resolutions were duly passed.

The result of the poll, including the proxy voting, is as follows:

Resolution	Description	For		Against		Discretion		Withheld	Total Votes Cast (excl. Votes Withheld)	For + Discretion	
		Votes	% Votes Cast	Votes	% Votes Cast	Votes	% Votes Cast	Votes		Votes	% Votes Cast
RES:001	REPORT AND ACCOUNTS REMUNERATION	560,824,152	99.99852%	325	0.00006%	8,000	0.00143%	3,000	560,832,477	560,832,152	99.99994%
RES:002	REPORT	560,789,302	99.99252%	33,975	0.00606%	8,000	0.00143%	4,200	560,831,277	560,797,302	99.99394%
RES:003	RE-ELECT MR W SIMON	560,823,652	99.99843%	825	0.00015%	8,000	0.00143%	3,000	560,832,477	560,831,652	99.99985%
RES:004	RE-ELECT DR.G S. JACOB	560,823,652	99.99843%	825	0.00015%	8,000	0.00143%	3,000	560,832,477	560,831,652	99.99985%
RES:005	RE-ELECT MR J BRANCACCIO	560,823,652	99.99843%	825	0.00015%	8,000	0.00143%	3,000	560,832,477	560,831,652	99.99985%
RES:006	RE-ELECT MR G CERRONE	560,812,452	99.99643%	12,025	0.00214%	8,000	0.00143%	3,000	560,832,477	560,820,452	99.99786%
RES:007	RE-ELECT MR.B DENOYER	560,812,952	99.99673%	10,325	0.00184%	8,000	0.00143%	4,200	560,831,277	560,820,952	99.99816%
RES:008	APPOINTMENT OF AUDITORS	560,823,652	99.99843%	825	0.00015%	8,000	0.00143%	3,000	560,832,477	560,831,652	99.99985%
RES:009	DIRECTORS TO ALLOT SHARES	560,822,952	99.99852%	325	0.00006%	8,000	0.00143%	4,200	560,831,277	560,830,952	99.99994%
RES:010	PRE-EMPTION RIGHTS	560,789,802	99.99260%	33,475	0.00597%	8,000	0.00143%	4,200	560,831,277	560,797,802	99.99403%

Further information on votes:

As at 17 August 2022, there were 1,415,040,468 ordinary shares in issue. Shareholders are entitled to one vote per ordinary share. Any vote withheld is not a vote in law and so has not been included in the calculation of the proportion of votes for and against any Resolution.

The resolutions were all passed on a poll, with votes cast in accordance with proxy voting instructions submitted to the Company by the relevant deadline, together with those cast at the AGM itself, and will be available on the National Storage Mechanism, <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The result of poll and proxy voting will also be available on the Company's website, www.okyopharma.com.

Enquiries:

OKYO Pharma Limited

Gary S. Jacob, *Chief Executive Officer*

Tel: +44 (0)20 7495 2379

Gabriele Cerrone, *Non-Executive Chairman*

Optiva Securities Limited (Broker)

Robert Emmet

Tel: +44 (0)20 3981 4173